| Description | |
|---|---|
| Catalogue Number | 14-783 |
| Trade Name |
|
| Description | PI3 Kinase (p110α(E545K)/p85α), 10 µg |
| Overview | Complex of N-terminal 6His-tagged, recombinant, full-length human p110α containing the mutation E545K and untagged, recombinant, full-length human p85α. |
| Background Information | The E545K substitution is a somatic mutation in p110α that has been associated with tumours of the colon and brain. Combined in vitro and in vivo studies have shown that this mutation confers higher lipid kinase activity than wild type, and is able to induce oncogenic transformation. |
| Product Information | |
|---|---|
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Complex of N-terminal 6His-tagged, recombinant, full-length human p110α containing the mutation E545K & untagged, recombinant, full-length human p85α. For use in Kinase Assays. |
| Key Applications |
|
| Biological Information | |
|---|---|
| Source | Coexpressed by baculovirus in Sf21 insect cells. |
| Specific Activity | For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme. |
| Entrez Gene Number |
|
| Entrez Gene Summary | Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. |
| Gene Symbol |
|
| Protein Target | PI3Kα/p85α |
| Purification Method | Ni2+/NTA-agarose |
| Target Sub-Family | PI3K/PI4K |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P42336 # Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2. SIZE: 1068 amino acids; 124284 Da SUBUNIT: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3 (By similarity). DISEASE: SwissProt: P42336 # Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500]. & Defects in PIK3CA are associated with breast cancer [MIM:114480]. & Defects in PIK3CA are associated with epithelial ovarian cancer (EOC) [MIM:604370]. SIMILARITY: SwissProt: P42336 ## Belongs to the PI3/PI4-kinase family. & Contains 1 C2 domain. & Contains 1 PI3K/PI4K domain. |
| Molecular Weight | p110α (E545K) MW = 125.3kDa, p85α MW = 83.7kDa. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Store at -70°C from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap. Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C. |
| Packaging Information | |
|---|---|
| Material Size | 10 µg |
| Material Package | Also available in 250 μg size --call for pricing and availability and reference catalog number 14-783M when ordering the 250 μg size. |